Alk­er­mes, Te­va set­tle patent suit around opi­oid-block­er Viv­it­rol, paving way for gener­ics af­ter three-year fight

Alk­er­mes has agreed to give Te­va a li­cense to make a gener­ic ver­sion of its opi­oid-block­ing drug Viv­it­rol in or­der to stop patent lit­i­ga­tion that be­gan in 2020, the com­pa­ny an­nounced Wednes­day.

Un­der the set­tle­ment, Te­va can start mak­ing a gener­ic ver­sion of the in­jectable start­ing on Jan. 15, 2027, or pos­si­bly ear­li­er un­der “cus­tom­ary cir­cum­stances.” Alk­er­mes’ patent for the drug would have ex­pired in 2029.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.